Is C-reactive protein an inflammation opsonin that signals colon cancer risk?

OLORECTAL CANCER IS A LEADING CAUSE OF CANCERrelated morbidity and mortality in the Western world. A personal history of inflammatory bowel disease (IBD) is a well-established risk factor for colorectal cancer. Recent data suggest that the risk of colorectal cancer for individuals with IBD increases by 0.5% to 1.0% yearly, 8 to 10 years after diagnosis. 1 The magnitude of colorectal cancer risk increases with early age at IBD diagnosis,longerdurationofsymptoms,andextentofthedis

[1]  C. Serhan,et al.  Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. , 2001, The Journal of clinical investigation.

[2]  M. Mccarty.  Historical Perspective on C‐Reactive Protein , 1982, Annals of the New York Academy of Sciences.

[3]  L. Marnett,et al.  COX-2: a target for colon cancer prevention. , 2002, Annual review of pharmacology and toxicology.

[4]  I. Kushner,et al.  BIOSYNTHESIS OF C‐REACTIVE PROTEIN * , 1982, Annals of the New York Academy of Sciences.

[5]  J. Vane,et al.  Mechanism of action of anti-inflammatory drugs. , 1996, Scandinavian journal of rheumatology. Supplement.

[6]  P. Munkholm.  Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[7]  Thomas Francis,et al.  SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS , 1930, The Journal of experimental medicine.

[8]  L. Title,et al.  Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[9]  F. Giardiello,et al.  Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. , 2001, Gastroenterology.

[10]  T. Erlinger,et al.  C-reactive protein and the risk of incident colorectal cancer. , 2004, JAMA.

[11]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[12]  I. Kushner.  THE PHENOMENON OF THE ACUTE PHASE RESPONSE * , 1982, Annals of the New York Academy of Sciences.

[13]  Garret A. FitzGerald,et al.  COX-2 and beyond: approaches to prostaglandin inhibition in human disease , 2003, Nature Reviews Drug Discovery.

[14]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[15]  J. Wallace,et al.  A magic bullet for mucosal protection...and aspirin is the trigger! , 2003, Trends in pharmacological sciences.

[16]  C. Serhan,et al.  Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[18]  S. Devaraj,et al.  C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells , 2003, Circulation.

[19]  J. Baron,et al.  Nonsteroidal anti-inflammatory drugs and cancer prevention. , 2000, Annual review of medicine.